3Daughters, a Mansfield, MA-based clinical development company fueling evolutionary healthcare for women, raised $4.7M in Seed funding.
Backers included Thairm Bio, Argosy Foundation, Wexford Science and Technology, LLC, UMass Amherst, and new undisclosed investors. Previously, the company had announced the close of the first tranche of this financing round, exceeding $2M.
Funds will support development of game-changing IUD (intrauterine device) for contraception through an IND filing in early 2025.
Led by CEO Mary Beth Cicero, 3Daughters is a clinical development company focused on healthcare for women. Its technology platform is based on physics and geometry to deliver targeted therapy to the uterus. The first product, (3D-001), is a frameless, magnetic, non-hormonal intrauterine device (IUD) for long-acting contraception that conforms to a woman’s body. Combined with its patented Slider™ system (for insertion and retrieval), this integrated system is expected to eliminate the steps in the insertion process as well as the nuisance factor of strings (needed for removal).
3Daughters has launched a Series A financing round of $15M to fund 3D-001’s first-in-human Phase 1 study expected to start following IND approval in 2025.
FinSMEs
11/07/2024